Sahni, Jayashree
Novartis (Switzerland)
3 papers on CoChatORCID 0000-0002-0970-8211
Most cited papers
- Verified
Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial
Khanani, A. M., Patel, S. S., Ferrone, P. J., Osborne, A., Sahni, J., Grzeschik, S., Basu, K., Ehrlich, J. S., Haskova, Z., & Dugel, P. U. (2020) · JAMA Ophthalmology
Retinal Diseases and TreatmentsOcular Diseases and Behçet’s Syndrome
Cited by 183
- Verified
Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial
Sahni, J., Dugel, P. U., Patel, S. S., Chittum, M. E., Berger, B., del Valle Rubido, M., Sadikhov, S., Szczesny, P., Schwab, D., Nogoceke, E., et al. (2020) · JAMA Ophthalmology
Retinal Diseases and TreatmentsOcular Diseases and Behçet’s Syndrome
Cited by 129
- Verified
Real-world safety and effectiveness of voretigene neparvovec: results up to 2 Years from the prospective, registry-based PERCEIVE study
Fischer, M. D., Simonelli, F., Sahni, J., Holz, F. G., Maier, R., Fasser, C., Suhner, A., Stiehl, D. P., Chen, B., Audo, I., et al. (2024) · Biomolecules
Retinal Development and DisordersVirus-based gene therapy research
Cited by 70
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free